Registers of multiple sclerosis in Denmark

Acta Neurologica Scandinavica

Volumn 132, Issue S199, 2015, Pages 4-10

  Koch Henriksen, N ^a,b   Magyari, M ^b   Laursen, B ^c  

^a AARHUS UNIVERSITY   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Epidemiology; Incidence; Matching; Multiple sclerosis; National registry; Personal Id; Prevalence

Indexed keywords

CASE CONTROL STUDY; COHORT ANALYSIS; DENMARK; ENVIRONMENTAL EXPOSURE; FOLLOW UP; HUMAN; INCIDENCE; MULTIPLE SCLEROSIS; PREVALENCE; REGISTER; REVIEW; RISK; RISK FACTOR; SURVIVAL;

DENMARK; HUMANS; INCIDENCE; MULTIPLE SCLEROSIS; PREVALENCE; REGISTRIES;

EID: 84930385025     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12424     Document Type: Review

References (69)

1. Hyllested K. Disseminated sclerosis in Denmark: prevalence and geographical distribution. Copenhagen: J Jørgensen, 1956.
2. Allison RS, Millar JDH. Prevalence and familial incidence of disseminated sclerosis. Ulster Med J 1954;23(Suppl 2):5-49.
3. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
4. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
5. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6.
6. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011;39(Suppl. 7):30-3.
7. Koch-Henriksen N, Rasmussen S, Stenager E, Madsen M. The Danish Multiple Sclerosis Registry. History, data collection and validity. Dan Med Bull 2001;48:91-4.
8. Mason K, Thygesen LC, Stenager E, Bronnum-Hansen H, Koch-Henriksen N. Evaluating the use and limitations of the Danish National Patient Register in register-based research using an example of multiple sclerosis. Acta Neurol Scand 2012;125:213-7.
9. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011;39(Suppl. 7):22-5.
10. Koch-Henriksen N, Hyllested K. Epidemiology of multiple sclerosis: incidence and prevalence rates in Denmark 1948-64 based on the Danish Multiple Sclerosis Registry. Acta Neurol Scand 1988;78:369-80.
11. Koch-Henriksen N, Bronnum-Hansen H, Hyllested K. Incidence of multiple sclerosis in Denmark 1948-1982: a descriptive nationwide study. Neuroepidemiology 1992;11:1-10.
12. Koch-Henriksen N, Stenager E, Bronnum-Hansen H, Flachs EM. Increasing incidence of multiple sclerosis in Danish women [abstract]. Mult Scler 2006;12(Suppl. 1):S228.
13. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010;9:520-32.
14. Bentzen J, Flachs EM, Stenager E, Bronnum-Hansen H, Koch-Henriksen N. Prevalence of multiple sclerosis in Denmark 1950-2005. Mult Scler 2010;16:520-5.
15. Bronnum-Hansen H, Koch-Henriksen N, Hyllested K. Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey. Neurology 1994;44:1901-7.
16. Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127:844-50.
17. Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry 1998;65:56-9.
18. Pfleger CC, Flachs EM, Koch-Henriksen N. Social consequences of multiple sclerosis (1): early pension and temporary unemployment-a historical prospective cohort study. Mult Scler 2010;16:121-6.
19. Pfleger CC, Flachs EM, Koch-Henriksen N. Social consequences of multiple sclerosis: clinical and demographic predictors - a historical prospective cohort study. Eur J Neurol 2010;17:1346-51.
20. Pfleger CC, Flachs EM, Koch-Henriksen N. Social consequences of multiple sclerosis. Part 2. Divorce and separation: a historical prospective cohort study. Mult Scler 2010;16:878-82.
21. Bazelier MT, De VF, Bentzen J et al. Incidence of fractures in patients with multiple sclerosis: the Danish National Health Registers. Mult Scler 2012;18:622-7.
22. Haahr S, Koch-Henriksen N, Moller-Larsen A, Eriksen LS, Andersen HM. Increased risk of multiple sclerosis after late Epstein-Barr virus infection: a historical prospective study. Mult Scler 1995;1:73-7.
23. Nielsen TR, Rostgaard K, Nielsen NM et al. Multiple sclerosis after infectious mononucleosis. Arch Neurol 2007;64:72-5.
24. Nielsen TR, Rostgaard K, Askling J et al. Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. Mult Scler 2009;15:431-6.
25. Johansen C, Koch-Henriksen N, Rasmussen S, Olsen JH. Multiple sclerosis among utility workers. Neurology 1999;52:1279-82.
26. Hansen T, Skytthe A, Stenager E, Petersen HC, Bronnum-Hansen H, Kyvik KO. Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult Scler 2005;11:504-10.
27. Hansen T, Skytthe A, Stenager E, Petersen HC, Kyvik KO, Bronnum-Hansen H. Risk for multiple sclerosis in dizygotic and monozygotic twins. Mult Scler 2005;11:500-3.
28. Hjalgrim H, Rasmussen S, Rostgaard K et al. Familial clustering of Hodgkin lymphoma and multiple sclerosis. J Natl Cancer Inst 2004;96:780-4.
29. Nielsen NM, Westergaard T, Frisch M et al. Type 1 diabetes and multiple sclerosis: a Danish population-based cohort study. Arch Neurol 2006;63:1001-4.
30. Nielsen NM, Rostgaard K, Rasmussen S et al. Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer 2006;118:979-84.
31. Stenager E, Bronnum-Hansen H, Koch-Henriksen N. The risk of multiple sclerosis in nurses: a population-based epidemiological study. Mult Scler 2003;9:299-301.
32. Stenager E, Bronnum-Hansen H, Koch-Henriksen N. Risk of multiple sclerosis in nurse anaesthetists. Mult Scler 2003;9:427-8.
33. Nielsen NM, Frisch M, Rostgaard K et al. Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult Scler 2008;14:823-9.
34. Pfleger CC, Koch-Henriksen N, Stenager E, Flachs EM, Johansen C. Head injury is not a risk factor for multiple sclerosis: a prospective cohort study. Mult Scler 2009;15:294-8.
35. Munger KL, Bentzen J, Laursen B et al. Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult Scler 2013;19:1323-9.
36. Nielsen NM, Bager P, Stenager E et al. Cesarean section and offspring's risk of multiple sclerosis: a Danish nationwide cohort study. Mult Scler 2013;19:1473-7.
37. Nielsen NM, Jorgensen KT, Bager P et al. Socioeconomic factors in childhood and the risk of multiple sclerosis. Am J Epidemiol 2013;177:1289-95.
38. Nielsen NM, Svanstrom H, Stenager E et al. The use of valproic acid and multiple sclerosis. Pharmacoepidemiol Drug Saf 2015;24:262-8.
39. Norgaard M, Nielsen RB, Jacobsen JB et al. Use of penicillin and other antibiotics and risk of multiple sclerosis: a population-based case-control study. Am J Epidemiol 2011;174:945-948.
40. Magyari M, Koch-Henriksen N, Pfleger CC, Sorensen PS. Reproduction and the risk of multiple sclerosis. Mult Scler 2013;19:1604-9.
41. Magyari M, Koch-Henriksen N, Pfleger CC, Sorensen PS. Physical and social environtment and the risk of multiple sclerosis. Mult Scler Relat Disord 2014;3:600-6.
42. Koch-Henriksen N, Sorensen PS. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group. Mult Scler 2000;6:172-5.
43. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
44. Ross C, Clemmesen KM, Svenson M et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000;48:706-12.
45. Sorensen PS, Ross C, Clemmesen KM et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-91.
46. Sorensen PS, Ross C, Clemmesen KM et al. Antibodies to IFN-beta: the Danish National IFN-beta Project. Neurology 2003;61:S27-8.
47. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005;65:33-9.
48. Petersen B, Bendtzen K, Koch-Henriksen N, Ravnborg M, Ross C, Sorensen PS. Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler 2006;12:247-52.
49. Ross C, Clemmesen KM, Sorensen PS, Koch-Henriksen N, Bendtzen K. Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis. Mult Scler 2006;12:39-46.
50. Sorensen PS, Koch-Henriksen N, Ravnborg M et al. Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey. Mult Scler 2006;12:253-64.
51. Sorensen PS, Koch-Henriksen N, Bendtzen K. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis? Mult Scler 2007;13:616-21.
52. Sorensen PS, Koch-Henriksen N, Flachs EM, Bendtzen K. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies? Mult Scler 2008;14:837-42.
53. Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. Mult Scler 2009;15:601-5.
54. Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sorensen PS. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 2009;16:420-3.
55. Sorensen PS, Jensen PE, Haghikia A et al. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler 2011;17:1074-8.
56. Sorensen PS, Koch-Henriksen N, Jensen PE. Neutralizing antibodies against interferon-beta do not predispose antibodies against natalizumab. Neurology 2011;76:759-60.
57. Jensen PE, Koch-Henriksen N, Sellebjerg F, Sorensen PS. Prediction of antibody persistency from antibody titres to natalizumab. Mult Scler 2012;18:1493-9.
58. Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health 2011;39(Suppl. 7):26-9.
59. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011;39(Suppl. 7):38-41.
60. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011;39(Suppl. 7):42-5.
61. Skytthe A, Kyvik KO, Holm NV, Christensen K. The Danish Twin Registry. Scand J Public Health 2011;39(Suppl. 7):75-8.
62. Blenstrup LT, Knudsen LB. Danish registers on aspects of reproduction. Scand J Public Health 2011;39(Suppl. 7):79-82.
63. Petersen L, Sorensen TI. The Danish Adoption Register. Scand J Public Health 2011;39(Suppl. 7):83-6.
64. Baker JL, Sorensen TI. The Copenhagen School Health Records Register. Scand J Public Health 2011;39(Suppl. 7):87-90.
65. Jensen VM, Rasmussen AW. Danish education registers. Scand J Public Health 2011;39:91-4.
66. Petersson F, Baadsgaard M, Thygesen LC. Danish registers on personal labour market affiliation. Scand J Public Health 2011;39(Suppl. 7):95-8.
67. Hansen J, Lassen CF. The Supplementary Pension Fund Register. Scand J Public Health 2011;39(Suppl. 7):99-102.
68. Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health 2011;39(Suppl. 7):103-5.
69. Christensen G. The Building and Housing Register. Scand J Public Health 2011;39(Suppl. 7):106-8.